Year : 2022  |  Volume : 24  |  Issue : 2  |  Page : 161-166

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial

1 Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-271, Korea Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China Wuhan Tongji Hospital, Tongji Medical College, Wuhan 430030, China First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 719054, China Kindai University Hospital, Ōsakasayama 589-8511, Japan Dokkyo Medical University Saitama Medical Center, Saitama 2-1-50, Japan Asian Medical Center, University of Ulsan, Seoul 138-040, Korea Janssen Medical Affairs Department, Beijing 100025, China Janssen Medical Affairs Department, Tokyo 101-0065, Japan Janssen Medical Affairs Department, Seoul 140-012, Korea Janssen Global Medical Affairs Department, Horsham, PA 08869, USA Janssen Research and Development, Spring House, PA 19477, USA Janssen Research and Development, Raritan, NJ 08869, USA BC Cancer and Vancouver Prostate Centre, Vancouver, BC V5Z 1G1, Canada Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence Address:
Ding-Wei Ye
Fudan University Shanghai Cancer Center, Shanghai 200032
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_64_21

Rights and Permissions

Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial was conducted at 260 sites in 23 countries. This subgroup analysis included patients enrolled in 62 participating centers in China, Japan, and Korea. Radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and PSA changes from baseline were compared between groups in the East Asian population. The intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups, respectively. The 24-month radiographic PFS rates were 76.1% and 52.3% in the apalutamide and placebo groups, respectively (apalutamide vs placebo: hazard ratio [HR] = 0.506; 95% confidence interval [CI], 0.302–0.849; P = 0.009). Median time to PSA progression was more favorable with apalutamide than placebo (HR = 0.210; 95% CI, 0.124–0.357; P < 0.001). Median maximum percentages of PSA decline from baseline were 99.0% and 73.9% in the apalutamide and placebo groups, respectively. The most common adverse event (AE) was rash in the apalutamide group, with a higher rate than that in the placebo group (37.3% vs 9.1%). The most common grade 3 or 4 AEs were rash (12 [10.9%]) and hypertension (12 [10.9%]) for apalutamide. The efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded388    
    Comments [Add]    

Recommend this journal